• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Inspections, Compliance, Enforcement, and Criminal Investigations

  • Print
  • Share
  • E-mail

Kingston Diagnostic Center 17-08-01 DETAIL

DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

 

New York District
Food & Drug Administration
300 Pearl Street, Suite 100
Buffalo, NY 14202

August 17, 2001
WARNING LETTER NYK 2001-114
CERTIFIED MAIL
RETURN RECEIPT REQUESTED

David M. Ryon, M.D.
Kingston Diagnostic Center
167 Schwenk Drive
Kingston, New York 12401
RE: Facility ID Number 175935

Dear Dr. Ryon:

Your facility was inspected on July 27, 2001 by a representative of the New York State Department of Health, acting on behalf of the Food and Drug Administration (FDA). This inspection revealed serious regulatory problems involving the mammography at your facility.

Under a United States Federal law, the Mammography Quality Standards Act of 1992, your facility must meet specific requirements for mammography. These requirements help protect the health of women by assuring that a facility can perform quality mammography. The inspection revealed the following repeat Level 2 finding at your facility:

  • Four of five mammography reports reviewed at random did not contain an acceptable assessment category.

The specific problem noted above appeared on your MQSA Facility Inspection Report which was issued to your facility at the close of the inspection. This problem is identified as a repeat Level 2 because it identifies a failure to meet a significant MQSA requirement and it indicates a failure by your facility to implement permanent correction of a problem found during your previous inspection.

Because this condition may be symptomatic of serious underlying problems that could compromise the quality of mammography at your facility, it represents a violation of the law which may result in FDA taking regulatory action without further notice to you. These actions include, but are not limited to, placing your facility under a Directed Plan of Correction, charging your facility for the cost of on-site monitoring,

assessing civil money penalties up to $10,000 for each failure to substantially comply with, or each day of failure to substantially comply with MQSA standards, suspension or revocation of your facility?s FDA certificate, or obtaining a court injunction against further mammography.

It is necessary for you to act on this matter immediately. Please explain to this office in writing within fifteen (15) working days from the date that you receive this letter each step your facility is taking to correct this violation and to prevent the recurrence of similar violations. Your response should include mammography reports demonstrating the use of acceptable assessment categories.

In addition, your response should address the Level 2 and repeat Level 3 findings that were listed on the inspection report provided at the close of the inspection. The Level 2 and repeat Level 3 findings are:

  • Failure to establish and/or follow adequate written procedures for collecting and resolving consumer complaints.
  • Failure to produce documents verifying that the interpreting physician [redacted] met the continuing education requirement of having taught or completed at least 15 category 1 continuing medical education units in mammography in 36 months.
  • Failure to conduct a medical audit and outcome analysis for the facility as a whole.
  • Failure to conduct a medical audit and outcome analysis for each individual interpreting physician.
  • Failure to conduct a medical audit and outcome analysis annually for the facility.
  • Failure to have the required personnel qualification documents available during the inspection.

Please submit your response to the above issues to the attention of Lisa M. Utz, Compliance Officer, U.S. Food and Drug Administration, 300 Pearl Street, Suite 100, Buffalo, NY 14202, telephone (716)551-4461 ext. 3117.

Finally, you should understand there are many FDA requirements pertaining to mammography. This letter pertains only to findings of your inspection and does not necessarily address other obligations you have under the law. You may obtain general information about all of FDA?s requirements for mammography facilities by contacting the Mammography Quality Assurance Program, Food and Drug Administration, P.O. Box 6057, Columbia, Maryland 21045-6057 (1-800-838-7715), or through the Internet at http://www.fda.gov.

Sincerely,

/s/

Robert L. Hart

Acting District Director